Results 1 to 10 of about 14,237 (205)
Genes and Diseases, 2022 As a BET bromodomain inhibitor, JQ1 has been proven have efficacy against a number of different cancers. In terms of male reproduction, JQ1 may be used as a new type of contraceptive, since JQ1 treatment in male mice could lead to germ cell defects and a
Mengmeng Sang +2 more
exaly +4 more sources
The BET inhibitor JQ1 targets fat metabolism and counteracts obesity
Journal of Advanced ResearchIntroduction: Obesity, one of the most frequent health problems in the adult population, is a condition characterized by excessive white adipose tissue accumulation and accompanied by the increased risk to develop other disorders such as type II diabetes,
Claudia Fornelli +7 more
doaj +4 more sources
Cancer Medicine, 2019 Aim JQ1, a BET bromodomain inhibitor, is a promising therapeutic approach for bladder cancer (BC). Our study aimed to determine whether autophagy is induced by JQ1 and its potential role toward proliferation in BC.
Jianbin Ma, Tie Chong
exaly +3 more sources
Protective effect of the BET protein inhibitor JQ1 in cisplatin-induced nephrotoxicity [PDF]
American Journal of Physiology - Renal Physiology, 2018 As a potent chemotherapy drug, cisplatin is also notorious for its side-effects including nephrotoxicity in kidneys, presenting a pressing need to identify renoprotective agents. Cisplatin nephrotoxicity involves epigenetic regulations, including changes in histone acetylation.
Liping Sun +2 more
exaly +4 more sources
Modulation of Virulence-Associated Traits in Aspergillus fumigatus by BET Inhibitor JQ1 [PDF]
Microorganisms, 2022 Aspergillus fumigatus is a disease-causing, opportunistic fungus that can establish infection due to its capacity to respond to a wide range of environmental conditions.
Anastasia Orekhova +12 more
doaj +6 more sources
Bromodomain Inhibitor JQ1 Provides Novel Insights and Perspectives in Rhabdomyosarcoma Treatment [PDF]
International Journal of Molecular Sciences, 2022 Rhabdomyosarcoma (RMS) is the most common type of pediatric soft tissue sarcoma. It is classified into two main subtypes: embryonal (eRMS) and alveolar (aRMS). MYC family proteins are frequently highly expressed in RMS tumors, with the highest levels correlated with poor prognosis.
Irène Marchesi +2 more
exaly +4 more sources
Pleiotropic effects of BET inhibition broadly boost tumor immunogenicity to CD8<sup><b>+</b></sup> T cells. [PDF]
OncoimmunologyBET inhibitors (BETi) have shown potential to augment tumor immunogenicity in melanoma. However, conflicting evidence exists regarding their precise mechanism of action, and their overall impact on melanoma immunogenicity and antitumoral T cell responses
Melief J +12 more
europepmc +2 more sources
The BET Inhibitor JQ1 Potentiates the Anticlonogenic Effect of Radiation in Pancreatic Cancer Cells
Frontiers in Oncology, 2022 We reported previously that the BET inhibitor (BETi) JQ1 decreases levels of the DNA repair protein RAD51 and that this decrease is concomitant with increased levels of DNA damage.
Patrick L. Garcia +8 more
doaj +3 more sources
Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1
OncoImmunology, 2019 Human pancreatic ductal adenocarcinoma (PDAC) exhibits marginal responses to anti-PD-1/PD-L1 immunotherapy and its mechanism remains poorly understood. We have investigated the effect of anti-PD-L1 and c-Myc inhibition in PDAC.
Yu Pan, Qinglin Fei, Zheyang Zhang
exaly +2 more sources
Synergistic anti-proliferative activity of JQ1 and GSK2801 in triple-negative breast cancer
BMC Cancer, 2022 Background Triple-negative breast cancer (TNBC) constitutes 10–20% of breast cancers and is challenging to treat due to a lack of effective targeted therapies. Previous studies in TNBC cell lines showed in vitro growth inhibition when JQ1 or GSK2801 were
Nanda Kumar Yellapu +6 more
doaj +3 more sources